Merck & Co Inc (MRK): Next-Year EPS Estimate 87.61%
As of 2026-06-04, Merck & Co Inc (MRK) has a next-year EPS growth estimate of 87.61%.
MRK was first flagged by our screen on 2026-05-28, when analyst consensus for its next-year EPS growth was revised from 87.58% to 87.61%. Current-year growth is projected at -42.78%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- EPS growth next year
- 87.61%
- EPS growth this year
- -42.78%
- EPS next quarter (est)
- $2.11
- Last price
- $120.26
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 87.61% | -42.78% | $2.11 | $120.26 |
| 2026-06-03 | 87.61% | -42.78% | $2.11 | $114.70 |
| 2026-06-02 | 87.61% | -42.78% | $2.11 | $115.65 |
| 2026-06-01 | 87.61% | -42.78% | $2.11 | $115.17 |
| 2026-05-31 | 87.61% | -42.78% | $2.11 | $118.72 |
| 2026-05-28 | 87.61% | -42.78% | $2.11 | $119.89 |
| 2026-05-27 | 87.58% | -42.78% | $2.11 | $120.24 |
| 2026-05-26 | 87.58% | -42.78% | $2.11 | $119.72 |
| 2026-05-25 | 87.59% | -42.78% | $2.11 | $122.41 |
| 2026-05-24 | 87.59% | -42.78% | $2.11 | $122.41 |
| 2026-05-21 | 87.59% | -42.78% | $2.11 | $115.88 |
| 2026-05-20 | 87.59% | -42.78% | $2.11 | $113.00 |
| 2026-05-19 | 87.59% | -42.78% | $2.11 | $114.24 |
| 2026-05-18 | 87.68% | -42.78% | $2.11 | $112.56 |
| 2026-05-17 | 87.68% | -42.78% | $2.11 | $111.38 |
| 2026-05-14 | 87.68% | -42.78% | $2.11 | $113.41 |
| 2026-05-13 | 87.68% | -42.78% | $2.11 | $113.56 |
| 2026-05-12 | 87.68% | -42.78% | $2.11 | $112.37 |
| 2026-05-11 | 87.75% | -42.80% | $2.11 | $111.28 |
| 2026-05-10 | 87.75% | -42.80% | $2.11 | $111.38 |
| 2026-05-07 | 87.55% | -42.78% | $2.09 | $112.30 |
| 2026-05-06 | 87.55% | -42.81% | $2.08 | $113.56 |
| 2026-05-05 | 87.55% | -42.81% | $2.08 | $113.15 |
| 2026-05-04 | 88.24% | -42.83% | $2.08 | $113.11 |
| 2026-05-03 | 88.76% | -42.95% | $2.08 | $112.16 |
| 2026-04-30 | 88.72% | -43.17% | $2.09 | $109.18 |
| 2026-04-29 | 88.72% | -43.17% | -$1.47 | $110.95 |
| 2026-04-28 | 88.72% | -43.17% | -$1.47 | $110.03 |
| 2026-04-27 | 88.72% | -43.17% | -$1.47 | $110.23 |
| 2026-04-26 | 88.72% | -43.17% | -$1.47 | $111.90 |
Recent News
- Eli Lilly Stocks Path To 30% UpsideTrefis
- Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection FractionBusiness Wire
- Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst callsThe Fly
- Mercks deal for Terns sparks debate over a possible biotech bidding warBioPharma Dive
- Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia TreatmentThe Daily Upside
- Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of TernsInvestor's Business Daily
- MSD spends $6.7bn to buy Terns Pharmaceuticals in cancer pipeline reinforcementPharmaceutical Technology
- Nasdaq bounces as oil price softens as US pushes for Iran talksProactive
- Arm stock skyrockets on chip news, On Holding CEO to step downYahoo Finance Video
- Merck to acquire Terns Pharmaceuticals for $6.7BProactive
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Merck & Co Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Merck & Co Inc (MRK) has a next-year EPS growth estimate of 87.61%, based on analyst consensus.
When was the latest EPS estimate revision for MRK?▾
The most recent revision occurred on 2026-05-28, when analysts adjusted the next-year EPS growth estimate from 87.58% to 87.61%.
What sector and industry does Merck & Co Inc belong to?▾
Merck & Co Inc operates in the Healthcare sector, specifically the Drug Manufacturers - General industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MRK appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Merck & Co Inc (MRK) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports